

control  
A<sup>1</sup>

X \ is R<sup>5</sup>, R<sup>6</sup> or R<sup>7</sup> monosubstituted by R<sup>8</sup>,

R<sup>5</sup> is linear or branched alkylene having 1-10 carbon atoms, in which one or two CH<sub>2</sub> groups may be replaced by -CH=CH- groups, O, S or SO,

**R<sup>6</sup>** is cycloalkyl or cycloalkylalkylene having 5-12 carbon atoms,

$R^7$  is phenyl or phenylmethyl,

R<sup>8</sup> is COOH, COOA, CONH<sub>2</sub>, CONHA, CON(A)<sub>2</sub> or CN,

A is alkyl having from 1 to 6 carbon atoms, and

Hal is F, Cl, Br or I,

or a physiologically acceptable salt or solvate thereof.

2. (Amended) A compound of the formula I according to Claim 1

(a) ~~5-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl]pentanoic acid;~~

(b) 4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl]benzoic acid;

(c) 4-[7-(3,4-methylene[-]dioxy[-]benzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl]butyric acid;

contd.  
d<sup>1</sup>

(d) 5-[7-(benzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl]pentanoic acid;


(e) [7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-ylmethoxy]acetic acid;

or a physiologically acceptable salt or solvate thereof.

Sub  
B1

3. (Amended) A process for the preparation of a compound of the formula I according to Claim 1 and salts thereof, comprising reacting

a) a compound of the formula II




II

in which

$R^3$ ,  $R^4$  and  $X$  are as defined in Claim 1, and  $L$  is Cl, Br, OH, SCH<sub>3</sub> or a reactive esterified OH group,

with a compound of the formula III



III

in which

$\text{R}^1$  and  $\text{R}^2$  are as defined above,

or

b) converting a radical X in a compound of the formula I into another radical X by hydrolysing an ester group to a COOH group or converting a COOH group into an amide or into a cyano group

and/or converting a compound of the formula I into one of its salts.

4. (Amended) A process for the preparation of a pharmaceutical preparation, comprising converting a compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts and solvates into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or solvent.

5. (Amended) A pharmaceutical preparation, comprising at least one compound of the formula I according to Claim 1 and/or a physiologically acceptable salt or solvate thereof.

6. (Amended) A compound of the formula I according to Claim 1 and physiologically acceptable salt or solvate thereof for combating a disorder of the cardiovascular system and for the treatment and/or therapy of potency disorders.

8. (Amended) Use of compounds of the formula I according to Claim 1 and/or their physiologically acceptable salts and solvates for the preparation of a medicament.
9. (Amended) A method of treating a disease of the cardiovascular system or a potency disorder, comprising administering a compound of claim 1.